Enterome to Present Clinical Data on EO2463 in B-cell Lymphoma at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 25, 2024 06:00 ET
|
Enterome
PARIS, April 25, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Announces Successful Completion of Phase 2 ROSALIE Study of EO2401 in Recurrent Glioblastoma
April 17, 2024 06:00 ET
|
Enterome
EO2401, a pioneering OncoMimics™ peptide-based immunotherapy, has demonstrated rapid activation and significant expansion of existing effector memory T cells against tumor-associated driver antigens...
Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024
March 06, 2024 06:42 ET
|
Enterome
PARIS, March 06, 2024 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Appoints Industry Veteran Dr. Peter Hirth to its Board of Directors
December 18, 2023 06:00 ET
|
Enterome
PARIS, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...
Enterome’s OncoMimics™ Immunotherapy EO2401 Significantly Improves Survival Rate in Recurrent Glioblastoma
November 20, 2023 06:00 ET
|
Enterome
Positive data from the ROSALIE Phase 1/2 trial presented at 2023 SNO Annual Meeting Median survival of 14.5 months and 18-months survival rate of 43.1% in a 26-patient cohort where EO2401 was...
Enterome to Present Updated Data From Phase 1/2 ROSALIE Trial of its Peptide-Based Immunotherapy EO2401 in Recurrent Glioblastoma at SNO 2023
November 13, 2023 06:00 ET
|
Enterome
PARIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its...
Enterome Presents Immune-Monitoring Data on EO2401 at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 01, 2023 07:00 ET
|
Enterome
Immune-monitoring data from the ongoing trials of EO2401 in adrenal tumors (SPENCER) and in recurrent glioblastoma (ROSALIE) High degree of homology with TAAs and robust immune responses validate the...
Enterome Selected to The Leukemia & Lymphoma Society’s Therapy Acceleration Program
October 30, 2023 06:00 ET
|
Enterome
LLS TAP is a strategic funding initiative to accelerate innovative blood cancer therapeutics Strategic equity investment of €3 million to support clinical advancement of EO2463 in Non-Hodgkin’s...
Enterome to Present Clinical Progress on its OncoMimics™ Pipeline at Upcoming Investor Meetings
October 25, 2023 08:33 ET
|
Enterome
PARIS, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on...
Enterome Presents Positive Data from Phase 1/2 SPENCER Trial of EO2401 in Adrenal Tumors at ESMO 2023 Congress
October 23, 2023 08:00 ET
|
Enterome
Updated results demonstrate sustained efficacy with a good safety profile Degree of tumor shrinkage on CT scans correlates with strength of CD8+ T cell specific immune response against EO2401...